Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 11/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | GPR6 | P46095 | 1/20 | 0.32 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9290062 | 0.93 | MALT1 (0.40) | MALT1TYK2KMT2ATNFIRAK4 | |
| SCHEMBL902832 | 0.91 | MALT1 (0.39) | MALT1TYK2KMT2ATNFIRAK4 | |
| SCHEMBL1148344 | 0.90 | MALT1 (0.44) | MALT1GRM4TRPV1 | |
| SCHEMBL12437107 | 0.89 | MALT1 (0.38) | MALT1TYK2KMT2ATRPV1 | |
| SCHEMBL15085539 | 0.85 | MALT1 (0.35) | MALT1TYK2KMT2AGRM4 | |
| SCHEMBL15085554 | 0.85 | MALT1 (0.35) | MALT1TYK2KMT2AGRM4TRPV1 | |
| SCHEMBL1148234 | 0.85 | MALT1 (0.35) | MALT1TYK2KMT2AGPR6 | |
| SCHEMBL1148434 | 0.85 | MALT1 (0.35) | MALT1TYK2KMT2AGPR6 | |
| SCHEMBL1148432 | 0.84 | MALT1 (0.34) | MALT1GPR6 | |
| SCHEMBL15085541 | 0.84 | MALT1 (0.36) | MALT1TYK2TNFIRAK4GPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481744-B2 | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2013-07-09 | — | — | US | disclosed |
| EP-2264021-B1 | PROCESS FOR PRODUCING AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20110034696-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264021-A1 | PROCESS FOR PRODUCING AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034696-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | SQOR, NOX5, NOX3 | MALT1 3967/4885TYK2 1145/4885KMT2A 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.